Investor Presentaiton
ENHERTU
Performance in Each Region (US, EU)
Global product sales: FY2023 Q1 results 81.7 Bn JPY (YOY +50.4 Bn JPY) FY2023 forecast 320.0 Bn JPY (YOY +112.5 Bn JPY)
>ENHERTU
US
trastuzumab deruxtecan
51.6 Bn JPY
20.0 Bn JPY
6.7 Bn JPY
17.8 Bn JPY
FY2022 Q1 FY2023 Q1 FY2022 Q1 FY2023 Q1
US
Europe
Daiichi-Sankyo
Product sales: FY2023Q1 results 51.6 Bn JPY (375 Mn USD) FY2023 forecast 195.1 Bn JPY (1.5 Bn USD)
Indication: HER2+ mBC 2L+, HER2 low mBC (post-chemo), HER2+ mGC 2L+, HER2 mutant mNSCLC 2L+
Market share status
HER2+ mBC 2L: Maintaining No.1 new patient share
HER2 low mBC: Maintaining No.1 new patient share and growing further
HER2+ MGC 2L: Maintaining No.1 new patient share
HER2 mutant mNSCLC 2L: Maintaining No.1 new patient share
Europe
Product sales: FY2023Q1 results 17.8 Bn JPY (130 Mn USD) FY2023 forecast 75.8 Bn JPY (583 Mn USD)
Indication: HER2+ mBC 2L+, HER2 low mBC (post-chemo), HER2+ MGC 2L+
Market share status
HER2+ MBC 2L: Maintaining No.1 new patient share in France, Germany and Spain
HER2 low mBC: Achieved No.1 new patient share in France and Germany
Other progress
Launched in Italy (Jul. 2023)
12View entire presentation